outlined earlier this month<\/a> by President Donald Trump\u2019s administration.<\/p>\nNovo also has started a temporary offer of $199 a month for the first two months of low doses of Wegovy and the drug\u2019s counterpart for diabetes, Ozempic. The new pricing will be available at pharmacies nationwide through home delivery and from some telemedicine providers.<\/p>\n
Rival Eli Lilly also plans price breaks for its weight-loss drug Zepbound once it gets a new, multi-dose pen on the market.<\/p>\n
Obesity treatments like Zepbound and Wegovy have soared in popularity in recent years. Known as GLP-1 receptor agonists, the drugs work by targeting hormones in the gut and brain that affect appetite and feelings of fullness.<\/p>\n
In clinical trials, they helped people shed 15% to 22% of their body weight — up to 50 pounds or more in many cases. But affordability has been a persistent challenge for patients.<\/p>\n
A recent poll by the nonprofit KFF found that about half of the people who take the treatments say it was hard to afford them.<\/p>\n
Previous research has shown that people have difficulty paying for a medication when the cost rises above $100 per month for a prescription or refill, said Stacie Dusetzina, a Vanderbilt University Medical Center professor and prescription drug pricing expert.<\/p>\n
She said new prices like those outlined by Novo are \u201cnot going to really move the needle for a person who doesn\u2019t have a pretty reasonable amount of disposable income.\u201d<\/p>\n
___<\/p>\n
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute\u2019s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will…\n","protected":false},"author":2,"featured_media":185418,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[274],"tags":[79,356,18,1465,3334,135,3955,19,17,462,40833,66],"class_list":{"0":"post-185417","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-business","9":"tag-donald-trump","10":"tag-eire","11":"tag-eli-lilly","12":"tag-general-news","13":"tag-health","14":"tag-health-care-costs","15":"tag-ie","16":"tag-ireland","17":"tag-medication","18":"tag-novo-nordisk-as","19":"tag-world-news"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115565592748289891","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/185417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=185417"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/185417\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/185418"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=185417"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=185417"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=185417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}